Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA OKs pivotal trial for AO (aqueous oxygen) heart attack system:

This article was originally published in Clinica

Executive Summary

TherOx is pressing on with a US, phase II clinical study of its aqueous oxygen (AO) system for treating heart attack, after gaining the green light from the FDA. The device, which will be tested at 10 US centres, hyperoxygenates a patient's blood with AO and then delivers the treated blood to oxygen-deprived areas of the heart following heart attack. Early research suggests that the therapy could dramatically improve heart function following primary angioplasty in patients suffering a major heart attack, says the Irvine, California firm, which has already CE-marked the device for sale in Europe.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT064562

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel